P73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints

被引:85
作者
Wang, Shulin
El-Deiry, Wafik S.
机构
[1] Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Hematol Oncol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA
关键词
D O I
10.1158/0008-5472.CAN-06-0511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Whereas the p53 tumor suppressor protein plays a central role in cellular checkpoints that respond to damage or stress to prevent tumorigenesis, the transcriptional control of the p53 gene has remained unclear. We show that chemotherapeutic agents induce p53 transcription and that p73 or p53 transactivates endogenous p53 expression through direct binding to the p53 promoter. Silencing of p53 or p73 by RNA interference significantly suppresses p53 transcription under physiologic conditions or in response to cellular stress. Mutational analysis of the human p53 promoter localized a p53 DNA-binding site, which confers p53- or p73-dependent p53 promoter activation. Importantly, impaired p53-mediated autoregulation of p53 transcription by inducible-interfering RNA results in aberrant cell cycle regulation and suppression of p53-mediated apoptosis. Thus, a positive feedback loop regulates human p53 expression and involves p73 and p53. Disruption of p53 transcription contributes to defective checkpoint control.
引用
收藏
页码:6982 / 6989
页数:8
相关论文
共 29 条
[1]   SUPPRESSION OF HUMAN COLORECTAL-CARCINOMA CELL-GROWTH BY WILD-TYPE-P53 [J].
BAKER, SJ ;
MARKOWITZ, S ;
FEARON, ER ;
WILLSON, JKV ;
VOGELSTEIN, B .
SCIENCE, 1990, 249 (4971) :912-915
[2]   Additive effect between NF-κB subunits and p53 protein for transcriptional activation of human p53 promoter [J].
Benoit, V ;
Hellin, AC ;
Huygen, S ;
Gielen, J ;
Bours, V ;
Merville, MP .
ONCOGENE, 2000, 19 (41) :4787-4794
[3]   p53: 25 years of research and more questions to answer [J].
Bourdon, JC ;
De Laurenzi, V ;
Melino, G ;
Lane, D .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (04) :397-399
[4]   Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells [J].
Burns, TF ;
Fei, PW ;
Scata, KA ;
Dicker, DT ;
El-Deiry, WS .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (16) :5556-5571
[5]   THE TUMOR-SUPPRESSOR P53 REGULATES ITS OWN TRANSCRIPTION [J].
DEFFIE, A ;
WU, HY ;
REINKE, V ;
LOZANO, G .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (06) :3415-3423
[6]   The role of p53 in chemosensitivity and radiosensitivity [J].
El-Deiry, WS .
ONCOGENE, 2003, 22 (47) :7486-7495
[7]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[8]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[9]   WILD-TYPE P53 CAN DOWN-MODULATE THE ACTIVITY OF VARIOUS PROMOTERS [J].
GINSBERG, D ;
MECHTA, F ;
YANIV, M ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :9979-9983
[10]   Nuclear factor -: κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug [J].
Hellin, AC ;
Calmant, P ;
Gielen, J ;
Bours, V ;
Merville, MP .
ONCOGENE, 1998, 16 (09) :1187-1195